
Prenetics Global rose 40.0% from $11.79 to $16.51, ahead of the S&P 500's +13.3%. Its worst day was Feb 20 (−11.7%), and its low came Nov 17 at $11.79.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Prenetics Global shares rose 13.3%, while the S&P 500 fell 0.3%.
+13.3% · S&P 500 −0.3%
Prenetics Global shares rose 15.5%, while the S&P 500 rose 0.5%.
+15.5% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-1.77 was reported on $36.6M revenue.
−7.7% · S&P 500 +0.5%
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board…
+18.1%, the year's best day · S&P 500 −1.3%
Prenetics Global shares rose 16.9%, while the S&P 500 rose 0.6%.
+16.9% · S&P 500 +0.6%
EPS of $-1.61 missed the $-0.49 estimate on $36.0M revenue (est. $37.9M); Q2 revenue guidance of $46.0M–$48.0M against the $45.7M consensus.
−8.0% · S&P 500 −1.6%
Prenetics Global shares rose 13.9%, while the S&P 500 fell 0.2%.
+13.9% · S&P 500 −0.2%
EPS of $-0.53 missed the $-0.45 estimate on $46.5M revenue (est. $49.1M); FY revenue guidance of $220.0M–$230.0M against the $215.2M consensus.
+0.2% · S&P 500 −0.7%
Prenetics Global closed at its highest level of the year, 122.6% above where the year started.
+1.8%, on 953K shares, the year's heaviest volume · S&P 500 +0.7%
Where it ended: a close of $16.51 on Nov 13, 2026. Up next: Q3 2026 earnings on Nov 18, 2026 (EPS est. $-0.86, revenue est. $63.2M).
Nothing in the past 12 months.
All PRE dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PRE and SPY from Benzinga historical bars. Not investment advice.